Physician profile
Cori Wright
NPI 1346523438
$3,537.89
in general payments reported to CMS, 2019-2025
23 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $240 · 2023: $815 · 2024: $655 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,990 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,989.99 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.79 | 2021-2025 | |
| Axsome Therapeutics, INC. | $388.29 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $318.99 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $295.43 | 2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $181.62 | 2023-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $164.31 | 2023-2025 | Rexulti |
| Edwards Lifesciences Corporation | $130.75 | 2022 | |
| Alkermes, INC. | $125.99 | 2024-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $117.45 | 2025 | |
| Almatica Pharma LLC | $110.71 | 2021-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $83.09 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $78.75 | 2025 | Fanapt |
| Acadia Pharmaceuticals INC | $72.27 | 2024-2025 | Nuplazid |
| Janssen Pharmaceuticals, INC | $64.72 | 2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $54.28 | 2024-2025 | Rexulti, Abilify Maintena |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $51.11 | 2021-2022 | |
| Nevro Corp. | $47.10 | 2021-2022 | |
| Amgen INC. | $24.74 | 2022 | |
| Idorsia Pharmaceuticals US INC | $23.79 | 2023 | Quviviq |
| Bausch Health US, LLC | $17.40 | 2025 | Aplenzin, Wellbutrin |
| Biodelivery Sciences International, INC. | $14.81 | 2021 | |
| Depuy Synthes Sales INC. | $14.76 | 2021 | |
| Terumo Bct, INC. | $10.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cori Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.